Embecta Corp. is a global diabetes care company. It is focused on providing solutions to people living with diabetes. It has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).

• Revenue in USD (TTM)1.08bn
• Net income in USD139.50m
• Incorporated2021
• Employees1.85k

• Location
  Embecta Corp300 Kimball Drive, Suite 300PARSIPPANY NJ 07054United StatesUSA
• Phone+1 (862) 401-0000
• Fax+1 (302) 655-5049
• Websitehttps://www.embecta.com/